Lincoln Nadauld, M.D., PhD., is the Chief of Precision Health at Intermountain Healthcare. Dr. Nadauld founded the Intermountain Precision Genomics program with a vision of finding solutions to improve health and disease through genomics and precision medicine without increasing costs. With his vision in mind, he oversees the clinical implementation of Precision Genomics across Intermountain’s 24 hospitals and 160 physician clinics. In addition, Dr. Nadauld facilitates genomic research to better understand the human genome. Dr. Nadauld conceived of and is leading the recently announced Heredigene, Population Study. A collaborative effort with deCODE Genetics in Iceland to collect and perform whole-genome sequencing on 500,000 participants in the Intermountain system. Dr. Nadauld completed clinical training in Medical Oncology at Stanford University School of Medicine, where he also completed a postdoctoral fellowship in solid tumor genomics. He remains a visiting scholar at Stanford University, focusing on cancer genomics and personalized medicine. His work has been published extensively and featured in a case study by Harvard Business Review, which discusses Intermountain Precision Genomics’ cutting-edge cancer care approach. Dr. Nadauld participated in the Precision Medicine Initiative Summit and roundtables at the White House with former President Barack Obama. He also participated in former Vice President Biden’s Cancer Moonshot Summit. His work in founding Intermountain Precision Genomics was recognized with the Utah Governor’s 32nd Annual Science Medal for Industry. This medal is the highest civilian award to be bestowed by the state of Utah, honors significant contributions to science and technology. Dr. Nadauld is married with five children and enjoys attending their many activities and events, water sports, fishing, and other athletic pursuits.
Recently, several unique partnerships for population sequencing studies have been launched. Various medical organizations and pharmaceutical and direct-to-consumer testing companies are included in these partnerships. The designed studies are expected to create new insights, identify new disease targets, and improve individualized patient care. In this session we will hear updates about several of these collaborative population studies to learn about the various opportunities created, the resulting benefits for each of the partners, and the challenges that need to be overcome in relation to data flow and data sharing.